26.17
3.77%
0.95
Pre-market:
26.18
0.010
+0.04%
Immunovant Inc stock is traded at $26.17, with a volume of 993.95K.
It is up +3.77% in the last 24 hours and down -11.20% over the past month.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
See More
Previous Close:
$25.22
Open:
$25.37
24h Volume:
993.95K
Relative Volume:
1.13
Market Cap:
$3.84B
Revenue:
-
Net Income/Loss:
$-272.55M
P/E Ratio:
-13.56
EPS:
-1.93
Net Cash Flow:
$-243.55M
1W Performance:
-9.45%
1M Performance:
-11.20%
6M Performance:
-15.23%
1Y Performance:
-22.57%
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
IMVT | 26.17 | 3.84B | 0 | -272.55M | -243.55M | -1.93 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Oct-13-23 | Upgrade | UBS | Neutral → Buy |
Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-01-23 | Initiated | BofA Securities | Buy |
Apr-25-23 | Initiated | Citigroup | Buy |
Mar-31-23 | Initiated | Piper Sandler | Overweight |
Mar-30-23 | Initiated | Stifel | Buy |
Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Sep-26-22 | Downgrade | UBS | Buy → Neutral |
Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
Jun-01-21 | Downgrade | Stifel | Buy → Hold |
Oct-28-20 | Initiated | UBS | Buy |
Oct-12-20 | Initiated | Guggenheim | Buy |
Oct-08-20 | Initiated | Stifel | Buy |
Oct-02-20 | Initiated | Credit Suisse | Outperform |
Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
Aug-25-20 | Initiated | Raymond James | Outperform |
Jul-29-20 | Initiated | H.C. Wainwright | Buy |
Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN
Immunovant stock hits 52-week low at $24.66 amid market shifts - Investing.com Nigeria
Principal Financial Group Inc. Purchases 391,436 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Technical Data - Stock Traders Daily
FMR LLC's Strategic Acquisition of Immunovant Inc Shares - GuruFocus.com
Immunovant: Pipeline Progressing With One Minor Delay (NASDAQ:IMVT) - Seeking Alpha
Immunovant (NASDAQ:IMVT) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat
Analysts Provide An Important Insights On Immunovant Inc (IMVT) - Stocks Register
Immunovant’s Strategic Advances in Autoimmune Therapies - TipRanks
Interesting IMVT Put And Call Options For March 2025 - Nasdaq
Immunovant's (IMVT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Immunovant Inc (IMVT) Quarterly 10-Q Report - Quartzy
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 - The Manila Times
Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses | IMVT Stock News - StockTitan
Immunovant Breaks Above 200-Day Moving AverageBullish for IMVT - Nasdaq
Emerald Mutual Fund Advisers Trust Has $5.24 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Where are the Opportunities in (IMVT) - Stock Traders Daily
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Position Boosted by abrdn plc - MarketBeat
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - MarketBeat
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - The Manila Times
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - ForexTV.com
Immunovant's chief medical officer sells $94,171 in stock By Investing.com - Investing.com Canada
Immunovant CTO Jay Stout sells $80,912 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) CTO Sells $80,912.20 in Stock - MarketBeat
Immunovant CTO Jay Stout sells $80,912 in stock - Investing.com India
Immunovant's chief medical officer sells $94,171 in stock - Investing.com India
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 By Investing.com - Investing.com Australia
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 - Investing.com
Immunovant CFO Eva Renee Barnett sells $94,172 in stock By Investing.com - Investing.com Australia
Immunovant's chief medical officer William Macias sells $91,782 in stock - Investing.com India
Immunovant's chief legal officer sells $82,339 in stock By Investing.com - Investing.com Australia
Immunovant's chief legal officer sells $82,339 in stock - Investing.com India
Exchange Traded Concepts LLC Buys 9,438 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant CFO Eva Renee Barnett sells $94,172 in stock - Investing.com
Immunovant CEO Peter Salzmann sells $261,845 in shares By Investing.com - Investing.com Australia
Immunovant CEO Peter Salzmann sells $261,845 in shares - Investing.com
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $91,782.52 in Stock - MarketBeat
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
IMVT (Immunovant Inc) has impressive results - US Post News
Raymond James gives an Outperform recommendation for Immunovant Inc (IMVT) - Knox Daily
Analyzing Ratios: Immunovant Inc (IMVT)’s Financial Story Unveiled - The Dwinnex
Immunovant: Switching Lead Candidates Increases Risk (NASDAQ:IMVT) - Seeking Alpha
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):